Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature.
Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature.
复制标题
DOI：
10.18632/oncotarget.13889
复制
发表时间：
2017-01-17
期刊：
影响因子：
--
通讯作者：
Chen M
中科院分区：
文献类型：
--
作者：
Davanian H;Balasiddaiah A;Heymann R;Sundström M;Redenström P;Silfverberg M;Brodin D;Sällberg M;Lindskog S;Kruger Weiner C;Chen M
颌骨成釉细胞瘤是牙源性肿瘤中最难治疗的肿瘤，复发率高。新的证据表明，非编码RNA（ncRNA）在肿瘤的发生和预后中起着重要作用。然而，成釉细胞瘤ncRNA表达数据缺乏。在这里，我们提出了成釉细胞瘤ncRNA签名的第一份报告。在该两步分析中使用了总共95个成釉细胞瘤病例和覆盖> 285.000个全长转录物的全局阵列转录组技术。该分析首先在测试队列中鉴定了31种上调的成釉细胞瘤相关ncRNA，伴随着癌症、剪接体、mRNA监视和Wnt的信号通路。在独立队列中的进一步验证指出，长非编码（lncRNA）和小核仁RNA（snoRNA）：LINC 340、SNORD 116 -25、SNORA 11、SNORA 21、SNORA 47和SNORA 65是成釉细胞瘤的独特ncRNA特征。重要的是，这些ncRNA的存在与BRAF-V600 E和SMO-L412 F突变、组织学类型或肿瘤位置无关，但与肿瘤大小呈正相关。总之，这项研究显示了成釉细胞瘤的ncRNA表达的系统研究，并阐明了这种侵袭性牙源性肿瘤的新的诊断和治疗靶点。
Ameloblastoma of the jaws remains the top difficult to treat odontogenic tumour and has a high recurrence rate. New evidence suggests that non-coding RNAs (ncRNAs) play a critical role in tumourgenesis and prognosis of cancer. However, ameloblastoma ncRNA expression data is lacking. Here we present the first report of ameloblastoma ncRNA signatures. A total of 95 ameloblastoma cases and a global array transcriptome technology covering > 285.000 full-length transcripts were used in this two-step analysis. The analysis first identified in a test cohort 31 upregulated ameloblastoma-associated ncRNAs accompanied by signalling pathways of cancer, spliceosome, mRNA surveillance and Wnt. Further validation in an independent cohort points out the long non-coding (lncRNAs) and small nucleolar RNA (snoRNAs): LINC340, SNORD116-25, SNORA11, SNORA21, SNORA47 and SNORA65 as a distinct ncRNA signature of ameloblastoma. Importantly, the presence of these ncRNAs was independent of BRAF-V600E and SMO-L412F mutations, histology type or tumour location, but was positively correlated with the tumour size. Taken together, this study shows a systematic investigation of ncRNA expression of ameloblastoma, and illuminates new diagnostic and therapeutic targets for this invasive odontogenic tumour.